$25.67
8.18% today
Nasdaq, Sep 16, 08:48 pm CET
ISIN
US88322Q1085
Symbol
TGTX
Sector
Industry

TG Therapeutics, Inc. Target price 2024 - Analyst rating & recommendation

TG Therapeutics, Inc. Classifications & Recommendation:

Buy
78%
Hold
11%
Sell
11%

TG Therapeutics, Inc. Price Target

Target Price $33.75
Price $23.73
Potential
Number of Estimates 8
8 Analysts have issued a price target TG Therapeutics, Inc. 2025 . The average TG Therapeutics, Inc. target price is $33.75. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 7 Analysts recommend TG Therapeutics, Inc. to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the TG Therapeutics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the TG Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 233.66 328.37
8,274.91% 40.53%
EBITDA Margin 9.01% 16.90%
100.13% 87.50%
Net Margin 5.96% 2.48%
100.07% 58.41%

8 Analysts have issued a sales forecast TG Therapeutics, Inc. 2024 . The average TG Therapeutics, Inc. sales estimate is

$328m
Unlock
. This is
5.29% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$412m 18.73%
Unlock
, the lowest is
$307m 11.38%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $234m 8,274.91%
2024
$328m 40.53%
Unlock
2025
$491m 49.47%
Unlock
2026
$640m 30.40%
Unlock
2027
$841m 31.39%
Unlock
2028
$1.1b 27.05%
Unlock

3 Analysts have issued an TG Therapeutics, Inc. EBITDA forecast 2024. The average TG Therapeutics, Inc. EBITDA estimate is

$55.5m
Unlock
. This is
45.70% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$96.1m 6.01%
Unlock
, the lowest is
$34.0m 66.74%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $21.1m 110.95%
2024
$55.5m 163.54%
Unlock
2025
$124m 123.14%
Unlock
2026
$173m 39.86%
Unlock

EBITDA Margin

2023 9.01% 100.13%
2024
16.90% 87.50%
Unlock
2025
25.23% 49.29%
Unlock
2026
27.06% 7.25%
Unlock

8 TG Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average TG Therapeutics, Inc. net profit estimate is

$8.1m
Unlock
. This is
91.25% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$26.3m 71.67%
Unlock
, the lowest is
$-27.9m 130.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $13.9m 106.16%
2024
$8.1m 41.66%
Unlock
2025
$115m 1,316.36%
Unlock
2026
$183m 58.66%
Unlock
2027
$376m 105.93%
Unlock
2028
$520m 38.27%
Unlock

Net Margin

2023 5.96% 100.07%
2024
2.48% 58.41%
Unlock
2025
23.46% 845.97%
Unlock
2026
28.55% 21.70%
Unlock
2027
44.74% 56.71%
Unlock
2028
48.69% 8.83%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ 0.09 0.05
106.16% 44.44%
P/E 452.00
EV/Sales 10.87

8 Analysts have issued a TG Therapeutics, Inc. forecast for earnings per share. The average TG Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.05
Unlock
. This is
91.67% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.17 71.67%
Unlock
, the lowest is
$-0.18 130.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $0.09 106.16%
2024
$0.05 44.44%
Unlock
2025
$0.74 1,380.00%
Unlock
2026
$1.18 59.46%
Unlock
2027
$2.43 105.93%
Unlock
2028
$3.36 38.27%
Unlock

P/E ratio

Current 39.54 820.22%
2024
452.00 1,043.15%
Unlock
2025
31.91 92.94%
Unlock
2026
20.11 36.98%
Unlock
2027
9.77 51.42%
Unlock
2028
7.06 27.74%
Unlock

Based on analysts' sales estimates for 2024, the TG Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

10.87
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
11.19
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10.29 83.85%
2024
10.87 5.63%
Unlock
2025
7.27 33.10%
Unlock
2026
5.58 23.31%
Unlock
2027
4.24 23.89%
Unlock
2028
3.34 21.29%
Unlock

P/S ratio

Current 10.60 83.75%
2024
11.19 5.59%
Unlock
2025
7.49 33.10%
Unlock
2026
5.74 23.31%
Unlock
2027
4.37 23.89%
Unlock
2028
3.44 21.29%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today